Compare Alexandria Real Estate Equities Inc (ARE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Novo Nordisk A/S — how do they compare? Alexandria Real Estate Equities Inc trades at $48.18 (market cap $8.28B), while Novo Nordisk A/S trades at $45.87 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 25.1× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| ARE | NVO | |
|---|---|---|
Market Cap | $8.28B | $207.85B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $63.98 |
52-Week Low | $40.41 | $35.29 |
Enterprise Value | $20.98B | $222.55B |
Dividend Yield | 5.99% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.35, down 2.79% today, with a bearish technical signal and mixed fundamentals. The stock shows a negative net income margin of -37.12% for 2025, though recent Q2 2026 FFO beat estimates. Analyst consensus is a 'Buy' with a $53.71 price target, but technical indicators suggest near-term pressure with support at $47 and resistance at $50.
Outlook remains cautious due to profitability challenges and high debt, but leasing momentum and strategic partnerships offer recovery potential. Risks include ongoing net losses and market volatility, while institutional interest and dividend payments provide some stability. Investors should weigh fundamental weaknesses against long-term real estate sector recovery prospects.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
